pharma · Dermatitis atopic · Cancer
Sanofi-Aventis U.S
Sanofi-aventis Healthcare Pty Ltd
Sanofi-aventis Healthcare Pty is a pharma organization headquartered in Sydney, AU. Primary therapeutic focus areas include Dermatitis atopic, Cancer, Immune system diseases, Asthma, Chronic Obstructive Pulmonary Disease
Bridgewater, USA HQ
177 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Bridgewater, USA
- Employees
- 177
- Programs
- 117
- Drugs
- 148
- Patents
- 0
EFC14462
Phase 3 · small molecule · Glycogen storage disease type II
EFC14462 for Glycogen storage disease type II is a Phase 3 program (small_molecule) at Sanofi-aventis Healthcare Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code EFC14462
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sanofi-aventis Healthcare Pty Ltd
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Glycogen storage disease type II
- Status
- active
- Trials
- 1